Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288041 · ClinicalTrials.gov registry record · Phase 2
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00288041: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00288041 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00288041, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving bortezomib together with paclitaxel and carboplatin works in treating patients with metastatic melanoma. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may help paclitaxel and carboplatin kill more tumor cells by making tumor cells more sensitive to these drugs
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00288041
The ClinicalTrials.gov registry entry for NCT00288041 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00288041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00288041 about?
NCT00288041 is a clinical study titled "Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma". This phase II trial is studying how well giving bortezomib together with paclitaxel and carboplatin works in treating patients with metastatic melanoma. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxe...
What is the current status of trial NCT00288041?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2005-10.
What interventions are being tested in trial NCT00288041?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00288041?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.